Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Resverlogix	Antibe Therapeutics	Bioventix	Gemini Therapeutics	Tiziana Life Sciences
Symbol	TSE:RVX	TSE:ATE	LON:BVXP	NASDAQ:GMTX	LON:TILS
Price Information
Current Price	C$0.89	C$4.44	GBX 4,069.98	$11.24	GBX 93.69
52 Week Range	N/A	Buy	N/A	Buy	N/A
MarketRank™
Overall Score	0.7	1.3	0.8	1.7	0.4
Analysis Score	0.0	3.5	0.0	3.5	0.0
Community Score	3.6	3.0	1.8	5.0	1.9
Dividend Score	0.0	0.0	1.7	0.0	0.0
Ownership Score	0.0	0.0	0.0	0.0	0.0
Earnings & Valuation Score	0.0	0.0	0.6	0.0	0.0
Analyst Ratings
Consensus Recommendation	N/A	Buy	N/A	Buy	N/A
Consensus Price Target	N/A	C$7.75	N/A	$22.00	N/A
% Upside from Price Target	N/A	74.55% upside	N/A	95.73% upside	N/A
Trade Information
Market Cap	C$208.25 million	C$202.05 million	£209.92 million	$483.31 million	£185.85 million
Beta	N/A	N/A	N/A	N/A	N/A
Average Volume	57,493	227,277	4,552	287,753	806,926
Sales & Book Value
Annual Revenue	N/A	C$9.33 million	£10.38 million	N/A	N/A
Price / Sales	N/A	21.66	20.42	N/A	N/A
Cashflow	C$0.00 per share	C$0.39 per share	GBX 113.31 per share	N/A	GBX 4.50 per share
Price / Cash	800.00	11.51	35.92	N/A	20.83
Book Value	C($0.17) per share	C$0.44 per share	GBX 197.90 per share	N/A	GBX 3.30 per share
Price / Book	N/A	10.18	0.21	N/A	N/A
Profitability
Net Income	N/A	N/A	N/A	N/A	N/A
EPS	C$0.01	C($0.79)	GBX 131.20	N/A	GBX (5.50)
Trailing P/E Ratio	80.91	N/A	31.02	0.00	N/A
Forward P/E Ratio	∞	∞	∞	∞	∞
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	N/A	N/A	N/A	N/A
Return on Equity (ROE)	N/A	N/A	N/A	N/A	N/A
Return on Assets (ROA)	N/A	N/A	N/A	N/A	N/A
Dividend
Annual Payout	N/A	C$0.05	GBX 0.88	N/A	N/A
Dividend Yield	N/A	1.13%	0.02%	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	0.67%	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	1.59%	N/A	N/A	17.85%
Current Ratio	0.17%	4.50%	11.69%	N/A	1.86%
Quick Ratio	0.08%	3.56%	11.42%	N/A	1.78%
Ownership Information
Institutional Ownership Percentage	N/A	N/A	N/A	N/A	N/A
Insider Ownership Percentage	N/A	N/A	N/A	N/A	N/A
Miscellaneous
Employees	25	47	12	29	8
Shares Outstanding	233.99 million	45.51 million	5.21 million	43.00 million	194.61 million
Next Earnings Date	4/23/2021 (Estimated)	7/23/2021 (Estimated)	N/A	N/A	6/14/2021 (Estimated)
Optionable	Not Optionable	Not Optionable	Not Optionable	Optionable	Not Optionable

Source	Headline
	Tiziana Life Sciences: Advancing the therapeutic pipeline proactiveinvestors.com - April 16 at 1:03 PM
	Tiziana Life Sci PLC - Tiziana Announces Plans to List Accustem in US proactiveinvestors.co.uk - April 15 at 9:44 AM
	TLSA: Accustem Converging on NASDAQ finance.yahoo.com - April 14 at 9:26 AM
	Tiziana Life Sciences plc Announces Plans to List Accustem Sciences Limited in the U.S. finance.yahoo.com - April 13 at 7:55 AM
	Tiziana Life Sciences intends to list Accustem Sciences in the U.S. seekingalpha.com - April 13 at 7:41 AM
	Tiziana Life Sciences (LON:TILS) Share Price Passes Above 50 Day Moving Average of $104.09 americanbankingnews.com - April 8 at 3:12 AM
	Can the Tiziana Life Sciences (TILS) share price continue climbing? fool.co.uk - April 6 at 7:20 AM
	Tiziana Life Sci PLC - Updated: Gabriele Cerrone, Bloomberg Interview proactiveinvestors.co.uk - April 1 at 12:58 AM
	Tiziana Life Sciences (LON:TILS) Shares Pass Below 50 Day Moving Average of $109.57 americanbankingnews.com - March 31 at 2:20 AM
	Tiziana Life Sci PLC - FDA Allows Foralumab Treatment for a SPMS Patient proactiveinvestors.co.uk - March 30 at 1:44 PM
	Tiziana To Treat Multiple Sclerosis Patient With Nasal Administration of Foralumab feeds.benzinga.com - March 30 at 11:32 AM
	Tiziana Life Sci PLC - Accustem Update proactiveinvestors.co.uk - March 30 at 8:43 AM
	Tiziana Announces the FDA Has Allowed Treatment for a Secondary Progressive Multiple Sclerosis (SPMS) Patient for the Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Expanded Access Program finance.yahoo.com - March 30 at 8:43 AM
	Tiziana Life Sciences plc: Accustem Update benzinga.com - March 30 at 7:47 AM
	Updated - Gabriele Cerrone, Chairman of Tiziana Life Sciences to give interview on Bloomberg ... apnews.com - March 30 at 3:42 AM
	Tiziana Life Sciences planning phase II clinical trial of monoclonal antibody treatment in patients with moderate to severe COVID-19 proactiveinvestors.com - March 30 at 3:42 AM
	Tiziana Life Sciences plans phase II trials of nasal antibody treatment in COVID-19 patients proactiveinvestors.com - March 30 at 3:42 AM
	Tiziana Plans Phase 2 Clinical Study in Moderate to Severe Covid-19 Patients with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody finance.yahoo.com - March 30 at 3:42 AM
	Is Tiziana Life Sciences stock a buy? fool.co.uk - March 29 at 12:39 PM
	Updated - Gabriele Cerrone, Chairman of Tiziana Life Sciences to give interview on Bloomberg Television US at 1:50 PM ET Tomorrow, 30 March 2021 finance.yahoo.com - March 29 at 12:39 PM
	Tiziana Life Sciences plc ("Tiziana" or the "Company") - Gabriele Cerrone, Chairman of Tiziana Life Sciences, to give interview on Bloomberg Television US at 1:20 PM ET Today finance.yahoo.com - March 29 at 7:38 AM
	Bitcoin Marks Huge Milestone In Mainstream Acceptance finance.yahoo.com - March 17 at 2:21 PM
	Tiziana Life Sciences to Present at the BIO CEO & Investor Digital Conference benzinga.com - February 16 at 10:24 AM
	Tiziana Life Sciences plc ("Tiziana" or the "Company") - Appointment of Director benzinga.com - February 5 at 2:41 AM
	Tiziana Life Sciences plc ("Tiziana" or the "Company") - Appointment of Director markets.businessinsider.com - February 5 at 2:10 AM

Date	Company	Brokerage	Action
5/23/2019	Resverlogix	Roth Capital	Reiterated Rating
2/25/2021	Antibe Therapeutics	Canaccord Genuity	Lower Price Target
9/24/2020	Antibe Therapeutics	Maxim Group	Set Price Target
7/15/2020	Antibe Therapeutics	Brookline Capital Management	Reiterated Rating
3/30/2020	Bioventix	FinnCap	Reiterated Rating
4/14/2021	Gemini Therapeutics	SVB Leerink	Initiated Coverage
3/9/2021	Gemini Therapeutics	Jefferies Financial Group	Initiated Coverage
3/8/2021	Gemini Therapeutics	The Goldman Sachs Group	Initiated Coverage
2/16/2021	Gemini Therapeutics	Stifel Nicolaus	Initiated Coverage
11/1/2019	Tiziana Life Sciences	Shore Capital	Reiterated Rating

(Data available from 4/19/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources